Stay updated with breaking news from Barry Wolfenson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
On track to initiate EscharEx® Phase III study in fourth quarter 2023NexoBrid® U.S. launch expected in early third quarter 2023Cash of over $57 million; Operating cash runway through... | May 30, 2023
16.03.2023 - 2022 total revenues of $26.5 million FDA approval of NexoBrid in December 2022; U.S. commercial availability expected in the second quarter of 2023 EscharEx Phase III protocol design is under review by the FDA; study to be initiated in the second ...
06.03.2023 - Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both bring extensive leadership experience and expertise in wound care and regenerative ... Seite 1
Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both bring extensive leadership... | March 6, 2023